Prospective Evaluation of Biomarker Profiles in Idiopathic Pulmonary Fibrosis

Completed

• Conditions: IPF

• Registration Number: NCT02151435
• Lead Sponsor: University of Michigan

Brief Summary

Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal, fibrotic disorder of the lung. The estimated prevalence is 30-80/100,000 in the United States with incidence estimates clearly rising. A major challenge in the care of patients with IPF is determining prognosis. The natural history of IPF is usually one of inexorable decline in lung function, ultimately resulting in death from respiratory failure. However, longitudinal physiologic decline in IPF is heterogeneous and difficult to predict in individual patients. While some patients with IPF may remain stable for years, in others the disease may progress rapidly over a relatively short time. We hypothesize that peripheral blood biomarkers based on extracellular matrix and matrix-modifying molecules will improve prognostication in patients with IPF.

Detailed Description

Not available

Study Timeline

• Study Start: 2013-08
• Study First Submitted: 2014-05-28
• Study First Submitted QC: 2014-05-29
• Study First Posted: 2014-05-30
• Status Verified: 2017-07
• Primary Completion: 2017-07
• Study Completion: 2017-07
• Last Update Submitted: 2017-07-25
• Last Update Posted: 2017-07-26

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 43

Inclusion Criteria

1. Age 35-80 years, inclusive
2. Diagnosis of IPF by HRCT or surgical lung biopsy
3. Able to understand and provide informed consent

Read More

Exclusion Criteria

1. AE-IPF during the prior year
2. Environmental exposure (occupational, drug, etc.) felt to be the etiology of the interstitial disease.
3. Diagnosis of collagen-vascular conditions according to published American College of Rheumatology criteria.
4. Significant airway obstruction (FEV1/FVC ratio < 0.60) or bronchodilator response, defined as a change in FEV1 ≥ 12% and absolute change > 200 mL OR change in FVC ≥ 12% and absolute change > 200 mL at baseline
5. Partial pressure of arterial oxygen (PaO2) < 55 mm Hg
6. Evidence of active infection
7. Listed for lung transplantation
8. Myocardial infarction, coronary artery bypass, or angioplasty within 6 months
9. Unstable angina pectoris or congestive heart failure requiring hospitalization or deteriorating within 6 months
10. Uncontrolled arrhythmia or hypertension
11. Known HIV, hepatitis C, cirrhosis, or chronic active hepatitis
12. Active substance and/or alcohol abuse
13. If you are pregnant or breastfeeding
14. Any condition other than IPF that is likely to result in your death within the next year
15. Any condition that, in the judgment of the PI, might cause participation in the study to be detrimental to you or that the PI deems makes you a poor candidate

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Progression-free survival	1 year	The primary outcome is your progression free survival as determined by time until any of: death, acute exacerbation of IPF, relative decline in FVC (liters) of at least 10% or DLCO (ml/min/mmHg) of 15% from baseline.

Trial Locations

Locations (1)

University of Michigan Medical Center; 🇺🇸 Ann Arbor, Michigan, United States